Sanofi (EPA:SAN) received a €97.00 ($115.48) price objective from investment analysts at Berenberg Bank in a research report issued on Monday. The firm presently has a “neutral” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 38.59% from the company’s previous close.
Other equities analysts have also recently issued reports about the company. Goldman Sachs Group set a €82.00 ($97.62) target price on Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd. Deutsche Bank set a €93.00 ($110.71) target price on Sanofi and gave the stock a “buy” rating in a report on Friday. S&P Global set a €83.00 ($98.81) target price on Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a target price on shares of Sanofi in a report on Thursday, November 2nd. Finally, Jefferies Group set a €80.00 ($95.24) target price on Sanofi and gave the stock a “neutral” rating in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of €86.88 ($103.42).
Shares of Sanofi (EPA:SAN) traded down €2.96 ($3.52) on Monday, hitting €69.99 ($83.32). The company had a trading volume of 3,770,000 shares, compared to its average volume of 2,220,000. Sanofi has a 12 month low of €69.79 ($83.08) and a 12 month high of €92.97 ($110.68). The company has a market cap of $88,410.00 and a PE ratio of 19.39.
ILLEGAL ACTIVITY NOTICE: “Sanofi (SAN) Given a €97.00 Price Target at Berenberg Bank” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/22/sanofi-san-given-a-97-00-price-target-at-berenberg-bank.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.